Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Scientists explain why coffee drinkers show lower risk of Type 2 diabetes

Why do heavy coffee drinkers have a lower risk of developing Type 2 diabetes, a disease on the increase around the world that can lead to serious health problems? Scientists are offering a new solution to that long-standing mystery in a report in ACS' Journal of Agricultural & Food Chemistry.

12 Jan 2012

USPTO issues patent to Unigene's peptide-based therapeutics for obesity

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office.

11 Jan 2012

Weight gain and other metabolic side effects of bipolar and schizophrenia drugs may be countered

A new study suggests that young people who are diagnosed with bipolar disorder and schizophrenia may be spared the side-effects of taking medication with the right diet and exercise program.

11 Jan 2012

Oramed files provisional patent application with USPTO for combination diabetes therapy

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.

11 Jan 2012

UCSF, Sanofi enter $3.1 million collaboration to identify diabetes drug targets

The University of California, San Francisco has signed an alliance with international pharmaceutical company Sanofi to share expertise in diabetes research and identify drug targets that could lead to new therapies for both type 1 and type 2 diabetes.

11 Jan 2012

Natural options against weight gain, sugar cravings, and insulin resistance

The holidays have come and gone, but many of us may still be battling intense sweet cravings leftover from the season's festivities. Excessive sugar cravings can be a sign that your blood glucose levels are out of balance which, if left unchecked, can lead to insulin resistance and Metabolic Syndrome, also known as "Pre-Diabetes."

11 Jan 2012

Brief adherence programs improve diabetes test results and depression symptoms

Patients simultaneously treated for both Type 2 diabetes and depression improve medication compliance and significantly improve blood sugar and depression levels compared to patients receiving usual care, according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania.

11 Jan 2012

Health Affairs assesses real-world lifestyle interventions to help prevent diabetes

An Emory University study published in the January issue of Health Affairs assesses real-world lifestyle interventions to help delay or prevent the costly chronic disease that affects nearly 26 million Americans.

11 Jan 2012

Statins may raise type 2 diabetes risk

A new study suggests statin medications used to lower cholesterol may raise the risk of diabetes to a slight extent. Study authors advise patients not to stop taking their medications without talking to a doctor, because statins' proven power to prevent heart attacks and strokes outweighs any potential increase in type 2 diabetes risk.

10 Jan 2012

Personalized medicine could offer a valuable tool to help combat the diabetic epidemic

With the trend in healthcare moving toward an era of personalized medicine, there is much anticipation and hope that customized approaches to prevention and treatment based on a person's genetic make-up will result in better health outcomes. Some advances, most notably with prevention and treatment of breast and colon cancer, have been widely heralded, raising questions about the potential for personalized medicine for other common diseases, such as diabetes.

10 Jan 2012

Delaying hypertension treatment in diabetic patients for up to a year is unlikely to be harmful

Confronted with a high blood pressure value in a diabetic patient, most doctors would treat aggressively with medications. According to new research, however, delaying drug treatment for up to a year is unlikely to be harmful. The delay allows doctors and their patients to focus on lifestyle changes such as salt restriction, weight management, and exercise.

10 Jan 2012

Scientists analyze effect of nationwide tax on sweetened beverages

Every year, Americans drink 13.8 billion gallons of soda, fruit punch, sweet tea, sports drinks, and other sweetened beverages—a mass consumption of sugar that is fueling soaring obesity and diabetes rates in the United States. Now a group of scientists at the University of California, San Francisco (UCSF), San Francisco General Hospital and Trauma Center (SFGH) and Columbia University have analyzed the effect of a nationwide tax on these sugary drinks.

10 Jan 2012

Insulin induces formation of new elastin in cultures of human aortic smooth muscle cells

New research reveals that insulin applied in therapeutic doses selectively stimulates the formation of new elastic fibers in cultures of human aortic smooth muscle cells.

10 Jan 2012

Amylin outlines key strategic priorities for 2012

Amylin Pharmaceuticals, Inc. today outlined its key strategic priorities for 2012, with a strong focus on driving the global commercial value of its diabetes franchise.

10 Jan 2012

Mylan confirms Actoplus Met XR patent challenge

Mylan Inc. today confirmed that the company has been sued by Takeda Pharmaceutical Company, Watson Pharmaceuticals and Andrx Labs in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Pioglitazone Hydrochloride and Extended-release Metformin Hydrochloride tablets, 15 mg/1000 mg and 30 mg/1000 mg.

9 Jan 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012